rmhTNF-α combined with cisplatin inhibits proliferation of A549 cell line in vitro / 中国医学科学杂志(英文版)

<p><b>OBJECTIVE</b>To explore the inhibitory effect of recombinant mutant human tumor necrosis factor-Α (rmhTNF-Α) in combination with cisplatin on human lung adenocarcinoma cell line A549.</p><p><b>METHODS</b>Human lung adenocarcinoma cell line A549 was treated with varying concentrations of rmhTNF-Α (0.38, 0.75, 1.50, 6.00 and 12.00 IU/ml) or cisplatin (3.91, 7.81, 15.63, 31.25 and 62.50 Μg/ml) for 24 hours. Viable cell number was analyzed by using crystal violet staining. The inhibitory rates of A549 cells growth by the two drugs were calculated. For analyzing whether there was a synergistic effect of rmhTNF-Α with cisplatin, A549 cells were treated with 0.75 IU/ml rmhTNF-Α and increased concentrations of cisplatin.</p><p><b>RESULTS</b>rmhTNF-Α or cisplatin inhibited the growth of A549 cell lines in a dose-dependent manner. The inhibitory effect of rmhTNF-Α combined with cisplatin was significantly greater than cisplatin alone at the same concentration (all P<0.01).</p><p><b>CONCLUSION</b>rmhTNF-Α combined with cisplatin might have synergistic inhibitory effect on human lung adenocarcinoma cell line A549.</p>

Observation on therapeutic effect of jianpi huoxue herbs combined with chemotherapy in treating post-operational colonic cancer patients / 中国中西医结合杂志

<p><b>OBJECTIVE</b>To observe and compare the therapeutic effect of Jianpi Huoxue herbs (JPHXH) combined with chemotherapy (CT) in treating post-operational colonic cancer patients with Pi deficiency Syndrome (PDS).</p><p><b>METHODS</b>Adopting randomized control trial method, 64 patients were divided into two groups. The treated group (n = 43) received JPHXH plus CT and the control group ( n = 21 ) received CT alone. A treatment course of 3 months was applied to both groups. Therapeutic effect, changes of PDS and incidence of adverse reaction in the two groups were observed.</p><p><b>RESULTS</b>The tumor remission rate in the treated group and the control group was 39.5 % and 33.3 %, respectively. The effective rate on PDS in the treated group and the control group was 72.1% and 19.0%, respectively, showing significant difference (P < 0.01). The incidence of adverse reaction was lower in the treated group than that in the control group (P < 0.05).</p><p><b>CONCLUSION</b>JPHXH is effective in treating post-operational colonic cancer patients with PDS and relieving the adverse reaction of chemotherapy to certain extent.</p>